Total Payments
$9,235
2024 Payments
$796.72
Companies
35
Transactions
455
Medicare Patients
26,296
Medicare Billing
$1.4M
Payment Breakdown by Category
Food & Beverage$9,085 (98.4%)
Education$149.98 (1.6%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $9,085 | 453 | 98.4% |
| Education | $149.98 | 2 | 1.6% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Boston Scientific Corporation | $2,533 | 54 | $0 (2022) |
| Amgen Inc. | $1,122 | 62 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $1,107 | 79 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $909.59 | 71 | $0 (2022) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $594.01 | 35 | $0 (2024) |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $466.64 | 30 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $355.00 | 23 | $0 (2024) |
| Abbott Laboratories | $286.17 | 9 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $208.96 | 13 | $0 (2024) |
| Astellas Pharma US Inc | $192.89 | 5 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $796.72 | 44 | Novartis Pharmaceuticals Corporation ($263.08) |
| 2023 | $823.25 | 40 | Novartis Pharmaceuticals Corporation ($210.91) |
| 2022 | $398.33 | 25 | Novartis Pharmaceuticals Corporation ($146.87) |
| 2021 | $394.92 | 26 | Novartis Pharmaceuticals Corporation ($139.70) |
| 2020 | $619.15 | 37 | Janssen Pharmaceuticals, Inc ($146.42) |
| 2019 | $1,290 | 68 | Boston Scientific Corporation ($398.65) |
| 2018 | $2,302 | 105 | Boston Scientific Corporation ($701.74) |
| 2017 | $2,611 | 110 | BOSTON SCIENTIFIC CORPORATION ($1,318) |
All Payment Transactions
455 individual payment records from CMS Open Payments — Page 1 of 19
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/16/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $9.61 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 12/11/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $10.78 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 12/09/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $17.74 | General |
| Category: DIABETES | ||||||
| 11/18/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $21.32 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 11/11/2024 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $19.79 | General |
| Category: Cardiovascular | ||||||
| 11/01/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $2.02 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 10/30/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $21.29 | General |
| Category: Cardiology | ||||||
| 10/25/2024 | Esperion Therapeutics, Inc. | NEXLETOL (Drug) | Food and Beverage | In-kind items and services | $16.32 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
| 10/17/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $24.96 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 10/14/2024 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $20.77 | General |
| Category: Cardiovascular | ||||||
| 09/09/2024 | PFIZER INC. | ELIQUIS (Drug) | Food and Beverage | In-kind items and services | $15.17 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 09/05/2024 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | LifeVest (Device) | Food and Beverage | Cash or cash equivalent | $23.13 | General |
| Category: Electromedical and Electrotherapeutic Apparatus | ||||||
| 09/04/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $24.58 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 08/16/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $11.79 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 08/02/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $18.20 | General |
| Category: Cardiology | ||||||
| 07/23/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $19.95 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 07/13/2024 | PFIZER INC. | ELIQUIS (Drug), PAXLOVID | Food and Beverage | In-kind items and services | $13.74 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 07/11/2024 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | LifeVest (Device) | Food and Beverage | Cash or cash equivalent | $20.32 | General |
| Category: Electromedical and Electrotherapeutic Apparatus | ||||||
| 07/03/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $7.56 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 06/24/2024 | Lexicon Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $17.89 | General |
| 06/21/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $5.10 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 06/17/2024 | Lexicon Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $18.27 | General |
| 06/06/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $6.23 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 05/28/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $17.55 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 05/20/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $20.62 | General |
| Category: Cardiology/Vascular Diseases | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 17 | 5,799 | 7,584 | $1.3M | $337,859 |
| 2022 | 18 | 7,157 | 9,099 | $1.3M | $348,063 |
| 2021 | 19 | 7,347 | 9,064 | $1.4M | $386,001 |
| 2020 | 21 | 5,993 | 8,006 | $1.4M | $344,776 |
Total Patients
26,296
Total Services
33,753
Medicare Billing
$1.4M
Procedure Codes
98
All Medicare Procedures & Services
98 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 1,060 | 2,496 | $769,096 | $212,734 | 27.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 195 | 195 | $92,535 | $22,147 | 23.9% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Facility | 2023 | 308 | 320 | $60,256 | $16,634 | 27.6% |
| 78452 | Nuclear medicine studies of heart muscle at rest and with stress and spect | Office | 2023 | 231 | 232 | $54,267 | $13,493 | 24.9% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2023 | 237 | 239 | $44,920 | $12,792 | 28.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 210 | 242 | $50,464 | $12,382 | 24.5% |
| 93010 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | Facility | 2023 | 1,535 | 1,586 | $39,682 | $9,920 | 25.0% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 683 | 779 | $37,556 | $8,214 | 21.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 51 | 57 | $23,711 | $6,392 | 27.0% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 59 | 89 | $18,791 | $5,449 | 29.0% |
| 93010 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | Office | 2023 | 590 | 706 | $17,664 | $3,710 | 21.0% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 48 | 48 | $14,833 | $3,592 | 24.2% |
| 93016 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | Office | 2023 | 170 | 170 | $11,183 | $2,711 | 24.2% |
| 93018 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | Office | 2023 | 227 | 227 | $9,843 | $2,417 | 24.6% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 23 | 23 | $9,227 | $2,247 | 24.4% |
| 78452 | Nuclear medicine studies of heart muscle at rest and with stress and spect | Facility | 2023 | 17 | 17 | $3,976 | $998.07 | 25.1% |
| 93244 | Heart rhythm review, and interpretation of continous external ekg over more than 48 hours up to 7 days | Office | 2023 | 24 | 25 | $1,656 | $436.86 | 26.4% |
| 93227 | Electrocardiogram (ecg) 2-day continuous with review by health care professional | Office | 2023 | 25 | 25 | $1,952 | $320.70 | 16.4% |
| 93016 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | Facility | 2023 | 20 | 20 | $1,315 | $313.95 | 23.9% |
| 93225 | Electrocardiogram (ecg) 2-day continuous | Office | 2023 | 24 | 24 | $1,738 | $275.73 | 15.9% |
| 93018 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | Facility | 2023 | 25 | 25 | $1,071 | $269.00 | 25.1% |
| 93227 | Electrocardiogram (ecg) 2-day continuous with review by health care professional | Facility | 2023 | 15 | 16 | $1,249 | $226.08 | 18.1% |
| 93242 | Heart rhythm recording continous external ekg over more than 48 hours up to 7 days | Office | 2023 | 22 | 23 | $883.89 | $184.22 | 20.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 924 | 2,082 | $641,152 | $175,680 | 27.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 348 | 564 | $117,611 | $32,805 | 27.9% |
About Dr. Gary Elkin, M.D
Dr. Gary Elkin, M.D is a Interventional Cardiology healthcare provider based in Savannah, Georgia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/07/2006. The National Provider Identifier (NPI) number assigned to this provider is 1114990678.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Gary Elkin, M.D has received a total of $9,235 in payments from pharmaceutical and medical device companies, with $796.72 received in 2024. These payments were reported across 455 transactions from 35 companies. The most common payment nature is "Food and Beverage" ($9,085).
As a Medicare-enrolled provider, Elkin has provided services to 26,296 Medicare beneficiaries, totaling 33,753 services with total Medicare billing of $1.4M. Data is available for 4 years (2020–2023), covering 98 distinct procedure/service records.
Ad
Practice Information
- Specialty Interventional Cardiology
- Location Savannah, GA
- Active Since 02/07/2006
- Last Updated 11/27/2012
- Taxonomy Code 207RI0011X
- Entity Type Individual
- NPI Number 1114990678
Products in Payments
- XARELTO (Drug) $909.59
- ENTRESTO (Drug) $705.01
- Corlanor (Drug) $582.01
- Repatha (Biological) $539.93
- LifeVest (Device) $466.64
- GENERAL - STENTS (Device) $446.49
- RESONATE (Device) $431.72
- LEQVIO (Drug) $402.06
- ELIQUIS (Drug) $388.43
- PRADAXA (Drug) $299.16
- JARDIANCE (Drug) $294.85
- GENERAL STENTS (Device) $234.54
- GENERAL - THERAPIES (Device) $231.47
- GENERAL THERAPIES (Device) $186.61
- Barostim Neo System (Device) $176.20
- ONYX FRONTIER (Device) $159.57
- Resolute (Device) $137.82
- WATCHMAN (Device) $135.10
- LATITUDE (Device) $134.17
- FARXIGA (Drug) $129.47
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.